Computer-aided discovery of anti-HIV agents.

A review is provided on efforts in our laboratory over the last decade to discover anti-HIV agents. The work has focused on computer-aided design and synthesis of non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) with collaborative efforts on biological assaying and protein crystallography. Numerous design issues were successfully addressed including the need for potency against a wide range of viral variants, good aqueous solubility, and avoidance of electrophilic substructures. Computational methods including docking, de novo design, and free-energy perturbation (FEP) calculations made essential contributions. The result is novel NNRTIs with picomolar and low-nanomolar activities against wild-type HIV-1 and key variants that also show much improved solubility and lower cytotoxicity than recently approved drugs in the class.

[1]  William L. Jorgensen,et al.  Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Sustiva through Computation of Resistance Profiles , 2000 .

[2]  A. Stepan,et al.  Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. , 2011, Chemical research in toxicology.

[3]  Lieven Baert,et al.  Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[4]  X Liu,et al.  Rationally designed multitarget anti-HIV agents. , 2013, Current medicinal chemistry.

[5]  D. Katzenstein,et al.  Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nonnucleoside Reverse Transcriptase Inhibitors , 2014, Antimicrobial Agents and Chemotherapy.

[6]  William L Jorgensen,et al.  Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility. , 2013, Bioorganic & medicinal chemistry letters.

[7]  W. L. Jorgensen,et al.  Prediction of drug solubility from structure. , 2002, Advanced drug delivery reviews.

[8]  M L Lamb,et al.  Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity. , 2000, Protein engineering.

[9]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[10]  Sheng Qi,et al.  Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: etravirine. , 2011, Journal of pharmaceutical sciences.

[11]  K. Anderson,et al.  Current Perspectives on HIV-1 Antiretroviral Drug Resistance , 2014, Viruses.

[12]  Robert A. Domaoal,et al.  Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase. , 2012, Bioorganic & medicinal chemistry letters.

[13]  William L. Jorgensen,et al.  Computational Binding Studies of Orthogonal Cyclosporin‐Cyclophilin Pairs , 1997 .

[14]  D I Stuart,et al.  Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. , 2000, Structure.

[15]  Julian Tirado-Rives,et al.  Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency. , 2013, Bioorganic & medicinal chemistry letters.

[16]  W. L. Jorgensen,et al.  Monte Carlo simulation of differences in free energies of hydration , 1985 .

[17]  Beat Ernst,et al.  Drug discovery today. , 2003, Current topics in medicinal chemistry.

[18]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[19]  T. Steitz,et al.  Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  W. L. Jorgensen,et al.  Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers. , 2014, ACS medicinal chemistry letters.

[21]  R. Siliciano,et al.  Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance. , 2015, ACS medicinal chemistry letters.

[22]  J Tirado-Rives,et al.  Viability of molecular modeling with pentium‐based PCs , 1996, Journal of computational chemistry.

[23]  Jonathan W. Essex,et al.  Monte Carlo Simulations for Proteins: Binding Affinities for Trypsin−Benzamidine Complexes via Free-Energy Perturbations , 1997 .

[24]  J. Polli,et al.  Central nervous system disposition and metabolism of Fosdevirine (GSK2248761), a non-nucleoside reverse transcriptase inhibitor: an LC-MS and Matrix-assisted laser desorption/ionization imaging MS investigation into central nervous system toxicity. , 2013, Chemical research in toxicology.

[25]  Julian Tirado-Rives,et al.  Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues. , 2004, Journal of medicinal chemistry.

[26]  William L Jorgensen,et al.  From docking false-positive to active anti-HIV agent. , 2007, Journal of medicinal chemistry.

[27]  William L. Jorgensen,et al.  Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives. , 2010, Bioorganic & medicinal chemistry letters.

[28]  William L Jorgensen,et al.  Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2006, Bioorganic & medicinal chemistry letters.

[29]  William L. Jorgensen,et al.  Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations. , 2008, Journal of the American Chemical Society.

[30]  Xianfeng Lin,et al.  Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses. , 2010, Bioorganic & medicinal chemistry letters.

[31]  Christopher M. Bailey,et al.  Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategy. , 2013, Journal of medicinal chemistry.

[32]  Julian Tirado-Rives,et al.  Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. , 2003, Journal of the American Chemical Society.

[33]  W. L. Jorgensen.  The Many Roles of Computation in Drug Discovery , 2004, Science.

[34]  K. Anderson,et al.  Novel Use of a Guanosine Prodrug Approach To Convert 2',3'-Didehydro-2',3'-Dideoxyguanosine into a Viable Antiviral Agent , 2002, Antimicrobial Agents and Chemotherapy.

[35]  G. Rishton.  Nonleadlikeness and leadlikeness in biochemical screening. , 2003, Drug discovery today.

[36]  William L. Jorgensen,et al.  Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase. , 2011, Journal of the American Chemical Society.

[37]  G. Klebe,et al.  Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. , 2002, Angewandte Chemie.

[38]  William L Jorgensen,et al.  Perspective on Free-Energy Perturbation Calculations for Chemical Equilibria. , 2008, Journal of chemical theory and computation.

[39]  William L. Jorgensen,et al.  Discovery of Wild-Type and Y181C Mutant Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors Using Virtual Screening with Multiple Protein Structures , 2009, J. Chem. Inf. Model..

[40]  William L Jorgensen,et al.  A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase. , 2014, Biochimica et biophysica acta.

[41]  William L Jorgensen,et al.  Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility. , 2013, Bioorganic & medicinal chemistry letters.

[42]  Minoru Ishikawa,et al.  Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. , 2011, Journal of medicinal chemistry.

[43]  Chevonne Reynolds,et al.  In search of a treatment for HIV--current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs). , 2012, Chemical Society reviews.

[44]  William L Jorgensen,et al.  Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group. , 2013, Journal of the American Chemical Society.

[45]  William L. Jorgensen,et al.  Search for Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase Using Chemical Similarity, Molecular Docking, and MM-GB/SA Scoring , 2007, J. Chem. Inf. Model..

[46]  William L. Jorgensen,et al.  FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2006 .

[47]  William L Jorgensen,et al.  Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2006, Bioorganic & medicinal chemistry letters.

[48]  J. Aqvist,et al.  A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.

[49]  W. L. Jorgensen,et al.  Structure‐Based Evaluation of C5 Derivatives in the Catechol Diether Series Targeting HIV‐1 Reverse Transcriptase , 2014, Chemical biology & drug design.

[50]  E. Clercq.  The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS). , 2013 .

[51]  M. Navia,et al.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.

[52]  W. L. Jorgensen,et al.  Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase. , 2015, Bioorganic & medicinal chemistry letters.

[53]  M M Morelock,et al.  Estimation and correlation of drug water solubility with pharmacological parameters required for biological activity. , 1994, Journal of pharmaceutical sciences.

[54]  J. Comer,et al.  Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound. , 2008, Journal of pharmaceutical and biomedical analysis.

[55]  Allan M Jordan,et al.  The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates. , 2011, Journal of medicinal chemistry.

[56]  William L Jorgensen,et al.  Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design. , 2012, Journal of the American Chemical Society.

[57]  W. L. Jorgensen.  Free energy calculations: a breakthrough for modeling organic chemistry in solution , 1989 .

[58]  Erik De Clercq,et al.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.

[59]  H. M. Vinkers,et al.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.

[60]  William L Jorgensen,et al.  Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. , 2011, Journal of medicinal chemistry.

[61]  William L Jorgensen,et al.  Efficient drug lead discovery and optimization. , 2009, Accounts of chemical research.

[62]  Julian Tirado-Rives,et al.  Molecular modeling of organic and biomolecular systems using BOSS and MCPRO , 2005, J. Comput. Chem..

[63]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[64]  J Tirado-Rives,et al.  Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs. , 2001, Bioorganic & medicinal chemistry letters.

[65]  J. Condra,et al.  Clinically effective HIV-1 protease inhibitors , 1997 .

[66]  G. Dutschman,et al.  Antiviral activity of 2′,3′-dideoxy-β-L-5-fluorocytidine (β-L-FddC) and 2′,3′-dideoxy-β-L-cytidine (β-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro , 1994 .

[67]  Julian Tirado-Rives,et al.  Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2006, Bioorganic & medicinal chemistry letters.

[68]  M L Lamb,et al.  Computational approaches to molecular recognition. , 1997, Current opinion in chemical biology.

[69]  R. Schinazi,et al.  Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus. , 1987, Biochemical pharmacology.

[70]  M L Lamb,et al.  Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. , 1998, Journal of medicinal chemistry.

[71]  Stephen H Hughes,et al.  In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). , 2005, Journal of medicinal chemistry.

[72]  W. L. Jorgensen,et al.  The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. , 1988, Journal of the American Chemical Society.